PMID- 19327895
OWN - NLM
STAT- MEDLINE
DCOM- 20090723
LR  - 20090623
IS  - 1879-355X (Electronic)
IS  - 0360-3016 (Linking)
VI  - 74
IP  - 4
DP  - 2009 Jul 15
TI  - Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors 
      in the head-and-neck region.
PG  - 1047-53
LID - 10.1016/j.ijrobp.2008.09.022 [doi]
AB  - PURPOSE: To determine the feasibility, safety, and efficacy of stereotactic body 
      radiation therapy (SBRT), also known as radiosurgery, in patients with 
      head-and-neck cancers. METHODS AND MATERIALS: Patients with pathologically proven 
      malignant lesions in the head-and-neck region were treated using single-dose SBRT 
      (S-SBRT) or fractionated SBRT (F-SBRT). Radiation doses were either 
      single-fraction 13-18 Gy for S-SBRT or 36-48 Gy in five to eight fractions for 
      F-SBRT. Response evaluation was based on clinical examinations and computed 
      tomography/magnetic resonance imaging scans. Pre- and post-SBRT tumor dimensions 
      were measured in three axes, and tumor volumes were calculated. Response 
      evaluation also was performed using World Health Organization criteria. RESULTS: 
      Fifty-five lesions were treated in 44 patients (25 men, 19 women). There were 
      three groups of patients: those with primary (n = 10), recurrent (n = 21), and 
      metastatic tumors (n = 13). The predominant histologic type was squamous cell 
      carcinoma (n = 33). The majority of lesions were treated using F-SBRT (n = 37). 
      Based on radiographic and clinical assessment, a 77% (complete + partial 
      response) response rate was noted. Percentage of reduction in tumor volume was 
      52% +/- 38% based on follow-up scans in 24 patients. Tumor control rates at 1 
      year were 83.3% and 60.6% in the primary and recurrent groups, respectively. 
      Median overall survival was 28.7, 6.7, and 5.6 months for the primary, recurrent, 
      and metastatic groups, respectively. Radiation Therapy Oncology Group Grade 1-2 
      mucositis was noted in all patients treated for oropharyngeal or laryngeal 
      lesions. CONCLUSIONS: The SBRT in single or fractionated doses offers a viable 
      treatment option for selected patients with primary, recurrent, and metastatic 
      head-and-neck cancers with functional preservation.
FAU - Siddiqui, Farzan
AU  - Siddiqui F
AD  - Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202, 
      USA.
FAU - Patel, Mehul
AU  - Patel M
FAU - Khan, Mumtaz
AU  - Khan M
FAU - McLean, Scott
AU  - McLean S
FAU - Dragovic, Jadranka
AU  - Dragovic J
FAU - Jin, Jian-Yue
AU  - Jin JY
FAU - Movsas, Benjamin
AU  - Movsas B
FAU - Ryu, Samuel
AU  - Ryu S
LA  - eng
PT  - Journal Article
DEP - 20090326
PL  - United States
TA  - Int J Radiat Oncol Biol Phys
JT  - International journal of radiation oncology, biology, physics
JID - 7603616
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Basal Cell/secondary/*surgery
MH  - Carcinoma, Squamous Cell/secondary/*surgery
MH  - Esophagitis/etiology
MH  - Feasibility Studies
MH  - Female
MH  - Head and Neck Neoplasms/mortality/pathology/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mucositis/etiology
MH  - Neoplasm Recurrence, Local/*surgery
MH  - Radiosurgery/adverse effects/*methods
MH  - Radiotherapy Dosage
MH  - Retreatment
MH  - Treatment Outcome
MH  - Tumor Burden
EDAT- 2009/03/31 09:00
MHDA- 2009/07/25 09:00
CRDT- 2009/03/31 09:00
PHST- 2008/07/16 00:00 [received]
PHST- 2008/09/26 00:00 [revised]
PHST- 2008/09/28 00:00 [accepted]
PHST- 2009/03/31 09:00 [entrez]
PHST- 2009/03/31 09:00 [pubmed]
PHST- 2009/07/25 09:00 [medline]
AID - S0360-3016(08)03498-6 [pii]
AID - 10.1016/j.ijrobp.2008.09.022 [doi]
PST - ppublish
SO  - Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1047-53. doi: 
      10.1016/j.ijrobp.2008.09.022. Epub 2009 Mar 26.